Phase II trial of PM 01183 as second-line therapy in patients with metastatic pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors PharmaMar
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
- 07 Apr 2014 Results from a retrospective study conducted using data from this trial have been presented at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) according to a PharmaMar media release.
- 10 Mar 2012 Planned end date 5 Feb 2014 added as reported by EudraCT.